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MaBACKGROUND Relative wall thickness (RWT), deﬁned as 2 times posterior wall thickness divided by the left ventricular
(LV) diastolic diameter, is a measure of LV geometry and may be a marker for adverse events in patients with LV
dysfunction.
OBJECTIVES The aim of this study was to investigate the relationship between RWT and the risk for ventricular
tachyarrhythmia (VA) in patients enrolled in the MADIT-CRT (Multicenter Automatic Deﬁbrillator Implantation Trial With
Cardiac Resynchronization Therapy) study.
METHODS The study population comprised 1,260 patients with mild heart failure and left bundle branch block.
RESULTS In a multivariable model, RWT was the most powerful echocardiographic measure for estimating the risk of
VAs compared with commonly used echocardiographic variables. Patients with low RWT (<0.24) had 83% (p < 0.001)
increased risk for VA and 68% (p < 0.001) increase in VA risk or death (VA/death) compared with patients with higher
RWT values. Each 0.01-unit decrease in RWT was associated with 12% (p < 0.001) and 10% (p < 0.001) increases in the
risk of VA and VA/death, respectively. Treatment with cardiac resynchronization therapy with deﬁbrillator (CRT-D; CRT
with implantable cardioverter-deﬁbrillator) was associated with a greater increase in RWT compared with implantable
cardioverter-deﬁbrillator at 12 months (4.6  6.8% vs. 1.5  2.7%; p < 0.001), and every 10% increase in RWT in CRT-D
patients was associated with 34% (p ¼ 0.027) and 36% (p ¼ 0.009) reductions in the risk of subsequent VA and VA/
death, respectively.
CONCLUSIONS In patients with mild heart failure and left bundle branch block, decreased RWT was associated
with an increase in the risk of VA and VA/death. CRT-D therapy was associated with a favorable increase in RWT
and reduction in risk of VA and VA/death. (Multicenter Automatic Deﬁbrillator Implantation Trial With Cardiac
Resynchronization Therapy [MADIT-CRT]; NCT00180271) (J Am Coll Cardiol 2016;67:303–12)
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ABBR EV I A T I ON S
AND ACRONYMS
CRT-D = cardiac
resynchronization therapy with
deﬁbrillator
HF = heart failure
ICD = implantable
cardioverter-deﬁbrillator
LBBB = left bundle branch
block
LVEDD = left ventricular
end-diastolic diameter
LVEDV = left ventricular
end-diastolic volume
LVEF = left ventricular ejection
fraction
NYHA = New York Heart
Association
PWT = posterior wall thickness
RWT = relative wall thickness
SWT = septal wall thickness
VA = ventricular
tachyarrhythmia
VF = ventricular ﬁbrillation
VT = ventricular tachycardia
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304to reduce VA incidence, most likely through a
mechanism of reverse remodeling in patients
with prolonged QRS duration and left bundle
branch block (LBBB) morphology (3–6).
Remodeling patterns of the LV can be
assessed by echocardiographic measurement
of relative wall thickness (RWT) and broadly
categorized as normal or adverse remodeling,
either eccentric or concentric. Previous
studies have shown that concentric remodel-
ing (high RWT) is associated with increased
morbidity and mortality in hypertensive pa-
tients with hypertrophic cardiomyopathy
(7–9). However, data regarding the relation
between the magnitude of eccentric hyper-
trophy (low RWT) and the risk of VA in pa-
tientswith dilated cardiomyopathy are scarce.TABLE 1 Patient Characteristics
Low RWT (<0.24)
(n ¼ 414)
High RWT ($0.24)
(n ¼ 846)
Age at enrollment, yrs 61.2  11.0 65.7  10.5*
Female 22 35*
SEE PAGE 313The present study was carried out in 1,260
patients with mild heart failure (HF) and
LBBB enrolled in the MADIT-CRT (Multi-
center Automatic Deﬁbrillator Implantation
Trial With Cardiac Resynchronization Ther-
apy) study. We aimed to investigate: 1) theCRT-D assigned therapy 58 61
Ischemic cardiomyopathy 43 45
Diabetes 30 30
Hypertension 57 66*
Smoking 14 9*
Prior atrial arrhythmia 10 12
Prior ventricular arrhythmia 9 5*
Prior HF hospitalization 40 38
Prior CABG 23 22
Antiarrhythmic treatment 8 6
ACE inhibitor or ARB 97 96
Aspirin 58 63
Beta-blocker 95 93
Diuretic 71 67
Statin 61 65
QRS duration, ms 168.0  21.3 160.6  17.7*
Heart rate, beats/min 69.1  11.0 67.9  10.9*
BMI, kg/m2 29.0  5.2 28.3  5.1*
Creatinine, mg/dl 1.15  0.31 1.13  0.32
BNP, pg/ml 147.5  185.2 100.9  128.4*
SBP, mm Hg 118.5  16.6 124.8  17.0*
LVEF, % 26.8  3.4 29.7  3.1*
LVEDV indexed by BSA, ml/m2 147.3  35.3 115.6  20.1*
LVESV indexed by BSA, ml/m2 108.3  28.8 81.5  15.7*
LAV indexed by BSA, ml/m2 52.4  10.8 44.5  8.6*
Values are mean  SD or %. *p < 0.05.
ACE ¼ angiotensin-converting enzyme; ARB ¼ angiotensin receptor blocker;
BMI ¼ body mass index; BNP ¼ B-type natriuretic peptide; BSA ¼ body surface
area; CABG ¼ coronary artery bypass graft; CRT-D ¼ cardiac resynchronization
therapy with deﬁbrillator; HF ¼ heart failure; LAV ¼ left atrial volume; LVEDV ¼
left ventricular end-diastolic volume; LVEF ¼ left ventricular ejection fraction;
LVESV ¼ left ventricular end-systolic volume; RWT ¼ relative wall thickness;
SBP ¼ systolic blood pressure.predictive value of RWT for the risk of VA compared
with other commonly used echocardiographic vari-
ables; 2) the relationship between LV morphology and
the risk of VA by measuring RWT; and 3) the remod-
eling effect of CRT-D on RWT.
METHODS
The study population comprised 1,260 patients
enrolled in the MADIT-CRT trial with LBBB at baseline
electrocardiogram (70% of the original 1,820 pa-
tients). The design and results of the MADIT-CRT
study have been reported previously (3,10). Brieﬂy,
patients who had ischemic cardiomyopathy (New
York Heart Association [NYHA] functional class I or II)
or nonischemic cardiomyopathy (NYHA functional
class II), LVEF #30%, normal sinus rhythm, and QRS
duration $130 ms, were randomized to receive CRT-D
or ICD therapy in a 3:2 ratio.
Device interrogation and programming were per-
formed as previously reported (10). All devices were
programmed to monitor and deliver therapy, anti-
tachycardia pacing, and/or shock therapy. All devices
were interrogated 1 month after enrollment and
thereafter every 3 months; arrhythmia episodes were
adjudicated by an independent core laboratory for
pre-deﬁned categories of appropriate or inappro-
priate therapy. A VA episode was deﬁned when
device-rendered therapy including antitachycardiapacing or shock was appropriately delivered. Ventric-
ular tachycardia (VT) was deﬁned as an episode with
ventricular rates between 180 and 250 beats/min;
ventricular ﬁbrillation (VF) was deﬁned as an episode
with ventricular rates >250 beats/min. Fast VT
was deﬁned as an episode with ventricular rates
$200 beats/min or VF.
Echocardiograms were obtained according to a
study-speciﬁc protocol at baseline, which was before
device implantation, and at 1 year. Echocardiography
recordings were analyzed ofﬂine by a single technician
in an independent core laboratory. Echocardiography
investigators analyzing the images were blinded to
treatment assignment and clinical outcome. Repro-
ducibility of the primary measures was assessed by the
primary observer reanalyzing 101 random studies.
LV volumes were measured with the Simpson disk
method in the apical 4- and 2-chamber views, and
LVEF was calculated according to the established
FIGURE 1 RWT Distribution
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Relative wall thickness (RWT) was normally distributed among 1,260 study patients (0.26  0.03).
TABLE 2 Risk of VT/VF* by Model
Models† HR† 95% CI p Value AIC†
Baseline† 3,441.66
RWT, per 0.01-U decrement 1.12 1.07–1.17 <0.001 3,420.12
LVEDV indexed by BSA, per 10 ml/m2 1.09 1.05–1.12 <0.001 3,425.21
LVESV indexed by BSA, per 10 ml/m2 1.10 1.06–1.15 <0.001 3,425.87
LVEF, %, per unit percentage 0.96 0.93–0.99 0.021 3,438.42
LAV indexed by BSA, per 10 ml/m2 1.23 1.10–1.38 <0.001 3,431.03
LV mass indexed by BSA, per 10 g/m2 1.05 0.99–1.12 0.125 3,441.38
LV mass/LVEDV ratio, per 0.01-U decrement 1.25 1.13–1.38 <0.001 3,424.38
*258 events. †Findings regarding risk associated with each echocardiographic parameter were obtained from
separate models, each adjusted for the following covariates: treatment arm, female sex, glomerular ﬁltration
rate, previous myocardial infarction, New York Heart Association class, QRS duration $150 ms, SBP, previous
ventricular arrhythmia (VA), and age at enrollment.
AIC ¼ Akaike Information Criterion; HR ¼ hazard ratio; VF ¼ ventricular ﬁbrillation; VT ¼ ventricular
tachycardia; other abbreviations as in Table 1.
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Linear measures were obtained either directly
from 2-dimensional echocardiograms or from 2-
dimensional–directed M-mode echocardiograms, us-
ing whichever was of better quality. Septal wall
thickness (SWT) and posterior wall thickness (PWT)
were assessed using linear measurements in para-
sternal long-axis view images as previously sug-
gested. RWT was calculated as 2 times PWT divided
by the LV diastolic diameter (11). A second method of
measuring RWT (the sum of SWT and PWT divided by
LV diastolic diameter) was also used to examine the
consistency of the results (12).
The coefﬁcients of variation for SWT and PWT were
9.6% and 10.3%, respectively. Patients were dichot-
omized between the lowest RWT tertile (<0.24) and
the upper 2 tertiles ($0.24), as pre-speciﬁed in this
substudy.
The primary endpoint was the combined endpoint
of VT or VF. Secondary endpoints included the
following separate endpoints: VT, VF, fast VT ($200
beats/min or VF), and the combined endpoint of VT,
VF, and death.
STATISTICAL ANALYSIS. Baseline clinical character-
istics were compared between RWT subgroups using
the chi-square or Fisher exact test for categorical
variables and the Wilcoxon rank-sum test forcontinuous variables. Categorical data are presented
as frequency and percentage and continuous vari-
ables as mean  SD or median and corresponding
interquartile range.
The cumulative probability of VA or mortality by
RWT subgroups was graphically displayed according
to the method of Kaplan and Meier, with comparison
of groups by the log-rank test. Multivariable Cox
proportional hazards regression analysis was used to
assess the association of RWT with reducing the risk
TABLE 3 Comparison of Predictive Value of Different Variables for VT/VF*
Models† Wald p Value HR 95% CI
Log
Likelihood Ratio
Chi-Square
Difference‡
Likelihood Ratio Test
p Value
Baseline 3,423.66
Models with LVEDV
LVEDV indexed by BSA, per 10 ml/m2 <0.001 1.09 1.05–1.12 3,405.21 18.46 <0.001
LVEDV indexed by BSA, per 10 ml/m2 0.096 1.04 0.99–1.09 3,397.41 26.26 <0.001
RWT, per 0.01-U decrement 0.005 1.08 1.02–1.15 0.005
Models with LVESV
LVESV indexed by BSA, per 10 ml/m2 <0.001 1.10 1.06–1.15 3,405.87 17.80 <0.001
LVESV indexed by BSA, per 10 ml/m2 0.134 1.05 0.99–1.11 3,397.93 25.73 <0.001
RWT, per 0.01-U decrement 0.005 1.09 1.03–1.15 0.005
Models with LVEF
LVEF, %, per unit percentage 0.021 0.96 0.93–0.99 3,418.42 5.24 0.022
LVEF, %, per unit percentage 0.979 1.00 0.96–1.04 3,400.11 23.55 <0.001
RWT, per 0.01-U decrement <0.001 1.12 1.06–1.17 <0.001
Models with LAV
LAV indexed by BSA, per 10 ml/m2 <0.001 1.23 1.10–1.38 3,411.03 12.63 <0.001
LAV indexed by BSA, per 10 ml/m2 0.153 1.10 0.97–1.25 3,398.11 25.55 <0.001
RWT, per 0.01-U decrement <0.001 1.10 1.04–1.15 <0.001
Models with LV mass
LV mass indexed by BSA, per 10 g/m2 0.125 1.05 0.99–1.12 3,421.38 2.29 0.130
LV mass indexed by BSA, per 10 g/m2 0.43 1.03 0.96–1.09 3,399.50 24.16 <0.001
RWT, per 0.01-U decrement <0.001 1.11 1.06–1.16 <0.001
*Values added to the baseline multivariate model alone and together with RWT. †Findings regarding risk associated with each echocardiographic parameter were obtained from
separate models, each adjusted for the following covariates: treatment arm, female sex, glomerular ﬁltration rate, previous myocardial infarction, New York Heart Association
functional class, QRS duration $150 ms, SBP, previous VA, and age at enrollment. ‡The chi-square difference was calculated by deducting the chi-square of each model from
the chi-square of the baseline model (83.30).
Abbreviations as in Tables 1 and 2.
TABLE 4
VT/VF
RWT, pe
LVEDD,
LVPWT,
LVSWT,
VT/VF/dea
RWT, pe
LVEDD,
LVPWT,
LVSWT,
*332 events
obtained fro
sex, glomer
QRS duratio
LVEDD ¼
thickness; L
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306of VT/VF, VT, VF, fast VT, and the combined endpoint
of VT/VF/death.
Covariates included in the multivariate models
were identiﬁed using a best subset procedure for the
VT/VF endpoint, choosing among a wide variety of
available baseline measures with the additionalRisk of VT and Death by Model*
Models† HR† 95% CI p Value AIC
r 0.01-U decrement 1.12 1.07–1.17 <0.001 3,420.12
per cm increase 1.59 1.28–1.96 <0.001 3,426.92
per mm decrease 1.32 1.10–1.60 0.003 3,435.03
per mm decrease 1.32 1.11–1.57 0.002 3,433.68
th
r 0.01-U decrement 1.10 1.05–1.14 <0.001 4,401.72
per cm increase 1.58 1.30–1.91 <0.001 4,402.24
per mm decrease 1.20 1.02–1.42 0.027 4,417.60
per mm decrease 1.19 1.02–1.39 0.024 4,417.37
. †Findings regarding risk associated with each echocardiographic parameter were
m separate models, each adjusted for the following covariates: treatment arm, female
ular ﬁltration rate, previous myocardial infarction, New York Heart Association class,
n $150 ms, SBP, previous VA, and age at enrollment.
left ventricular end-diastolic diameter; LVPWT ¼ left ventricular posterior wall
VSWT ¼ left ventricular septal wall thickness; other abbreviations as in Tables 1 and 2.stipulation that they needed to be statistically sig-
niﬁcant with an individual p value <0.05 for inclu-
sion. Thus, all models were adjusted for CRT-D
therapy, female sex, glomerular ﬁltration rate, pre-
vious myocardial infarction, NYHA functional class,
QRS duration $150 ms, systolic blood pressure,
previous VA, and age at enrollment.
For comparison of the predictive value of RWT with
other commonly used echocardiographic variables in a
multivariable model setting, the Akaike information
criterion (AIC) was used as a measure of model ﬁt, due
to the comparisons necessary among nonnested
models. Separate multivariable models were esti-
mated for each echocardiographic parameter, and the
AIC values were compared. The components of RWT,
left ventricular end-diastolic diameter (LVEDD) and
LVPWT, were also compared using AIC values with the
same multivariable adjustment. Finally, both the
continuous and dichotomized (at the ﬁrst tertile) RWT
values were ﬁt into multivariable models for a variety
of VA outcomes.
Additionally, we analyzed the incremental increase
to the predictive value of the model when RWT was
entered into a multivariate model in conjunction with
each echocardiographic variable in a pairwise fashion.
FIGURE 2 Event Probability by RWT
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Patients with low relative wall thickness (RWT) (<0.24 [lower tertile]) (orange) had a
signiﬁcantly higher risk for (A) ventricular arrhythmia (VA) and (B) VA or death compared
with patients with high RWT ($0.24 [2 upper tertiles]) (blue). *The values in the paren-
theses are Kaplan-Meier event rates.
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model with an echocardiographic variable with the
model after adding RWT. Because these models were
nested, we used a likelihood ratio test for the overall
ﬁt of the model, whereas the Wald test was used to
assess the signiﬁcance of the hazard ratio (HR) for
RWT. In a separate analysis, the relationship between
RWT percent changes from baseline to follow-up and
the risk of the primary and secondary endpoints
subsequent to the 1-year echocardiogram (landmark-
type analysis) was assessed using Cox proportional
hazards regression, again with the same multivariable
adjustments.
All statistical tests were 2-sided, and a p value<0.05
was considered statistically signiﬁcant. Analyses were
carried out with SAS software version 9.4 (SAS Insti-
tute, Cary, North Carolina).
RESULTS
The baseline clinical characteristics of 1,260 study
patients dichotomized into low (<0.24, lowest tertile)
and high RWT ($0.24) are shown in Table 1. (Further
separation into 3 tertiles is shown in Online Table 1).
Patients with low RWT were younger than patients
with high RWT but had a higher frequency of clinical
characteristics associated with more advanced HF,
such as lower LVEF, larger cardiac volumes, wider
baseline QRS duration, higher B-type natriuretic
peptide (BNP) levels, and a greater incidence of pre-
vious VA >3 months prior to enrollment. The high
RWT subgroup had a greater proportion of women
and a lower proportion of smokers.
RELATIONSHIP BETWEEN RWT AND VA. RWT was
normally distributed among study patients (0.26 
0.03) (Figure 1). We compared the risk associated with
several echocardiographic parameters (including
left ventricular end-diastolic volume [LVEDV], LV
end-systolic volume, left atrial volume, LVEF, LV
mass, and LV mass/LVEDV ratio) by constructing
separate multivariate models for the endpoint of VA
that included each echocardiographic parameter at a
time. (The baseline multivariate model is shown in
Online Table 2.)
The comparison of the model ﬁt was assessed using
the AIC (Table 2, further detailed comparison in
Online Table 3). The model that included RWT as an
echocardiographic measure had the best ﬁt (lowest
AIC value), thereby suggesting that RWT is the best
echocardiographic variable in predicting the risk of
VA compared with other commonly used echocar-
diographic parameters.
In a second analysis, we compared the incremental
increase to the predictive value of each model whenRWT was entered into a multivariate model with each
echocardiographic variable in a pairwise fashion
(compared with the baseline model of each echocar-
diographic variable). The comparison of the model ﬁt
was assessed using the likelihood ratio test, whereas
the Wald test was used to assess the signiﬁcance of
the HR for RWT (Table 3). Accordingly, RWT was a
signiﬁcant and superior predictor even when com-
bined with other echocardiographic variables and
added signiﬁcantly to the predictive capacity of all of
the models (lower log likelihood ratio).
TABLE 5 Risk of VT by RWT*
Outcome
(Number of Events)
Continuous RWT <0.24 Versus RWT $0.24
HR† 95% CI p Value HR‡ 95% CI p Value
VT/VF (n ¼ 258) 1.12 1.07–1.17 <0.001 1.83 1.42–2.37 <0.001
VT $200/VF (n ¼ 161) 1.15 1.09–1.21 <.001 1.93 1.39–2.66 <0.001
VT/VF/death (n ¼ 332) 1.10 1.05–1.14 <0.001 1.68 1.37–2.10 <0.001
VT (n ¼ 221) 1.11 1.06–1.17 <0.001 1.91 1.45–2.52 <0.001
VF (n ¼ 73) 1.08 1.00–1.17 0.065 1.61 0.99–2.60 0.054
*Adjusted for CRT-D therapy, female sex, glomerular ﬁltration rate, previous myocardial infarction, New York
Heart Association class, QRS duration $150 ms, SBP, previous VA, and age at enrollment. †HR per 0.01-unit
decrement of RWT. ‡HR for the lowest RWT tertile <0.24 versus upper 2 tertiles $0.24.
Abbreviations as in Tables 1 and 2.
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were signiﬁcant independent predictors of VT/VF and
VT/VF/death. LVEDD was a better predictor versus
LVPWT (lower AIC); however, these relationships
existed in an opposite manner: whereas wider LVEDD
was related to increased hazard, lower LVPWT was
harmful (Table 4). Importantly, the model with RWT
had a better ﬁt compared with its 2 components and
with the LV mass/LVEDV ratio (Tables 2 and 4).
Patients with low RWT (<0.24 [lower tertile]
vs. $0.24 [2 upper tertiles]) had a signiﬁcantly higherFIGURE 3 Multivariable Analysis of VA Risk by RWT
Variable Hazard Ratio and 95% C
CRT-D
ICD
LVEDV > 240
LVEDV <= 240
LVEF > 29
LVEF <= 29
LVESV > 170
LVESV <= 170
All
0.5 1 1.5 2 2
High RWT Low
The risk for ventricular arrhythmia (VA) was consistently and signiﬁcantl
echocardiographic and treatment arm subgroups (each p < 0.001). CRT-
ratio; ICD ¼ implantable cardioverter-deﬁbrillator; LVEDV ¼ left ventricu
LVESV ¼ left ventricular end-systolic volume.risk for VA and VA/death events (Figures 2A and 2B).
Consistent with these ﬁndings, multivariable analysis
demonstrated that lower RWT as either categorical or
continuous (i.e., every 0.01-U decrease in RWT) var-
iable was signiﬁcantly related to higher risk of the
entire spectrum of VA and combined outcome of VA
or death (Table 5). These ﬁndings were consistently
signiﬁcant, even after further adjustments to baseline
differences (BNP, body mass index, and smoking),
and in all pre-speciﬁed subgroups (Figure 3). Results
were also consistent when an alternative formula was
used for measuring RWT (SWT þ PWT divided by
LVEDD); each 0.01-U decrease in RWT was associated
with a respective 11% (HR: 0.89; 95% CI: 0.86 to 0.93;
p < 0.001) and 9% (HR: 0.91; 95% CI: 0.88 to 0.95;
p < 0.001) increase in the risk of VA and VA/death,
respectively.
THE EFFECT OF CRT-D ON RWT. CRT-D therapy was
associated with a greater increase in RWT compared
with ICD therapy at 12 months (4.6  6.8% vs. 1.5 
2.7%; p < 0.001). Among all study patients,
Kaplan-Meier survival analysis (Figure 4) showed that
the cumulative probability of a ﬁrst occurrence of
VT/VF 3 years after assessment of echocardiographicI
.5 3 4 5
 RWT
Events/Pts HR (95% CI) P value
138/756
132/504
160/608
110/652
100/596
170/664
163/614
107/646
270/1260
2.18 (1.56-3.05)
2.22 (1.58-3.12)
1.77 (1.28-2.44)
2.48 (1.63-3.77)
2.56 (1.68-3.88)
1.93 (1.42-2.62)
1.78 (1.29-2.45)
2.50 (1.61-3.86)
2.22 (1.75-2.82)
<.001
<.001
<.001
<.001
<.001
<.001
<.001
<.001
<.001
y higher with low relative wall thickness (RWT) in the pre-speciﬁed
D ¼ cardiac resynchronization therapy with deﬁbrillator; HR ¼ hazard
lar end-diastolic volume; LVEF ¼ left ventricular ejection fraction;
FIGURE 4 One-Year VA Risk by Change in RWT
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Patients who had a higher relative wall thickness (RWT) increase after 12 months with
cardiac resynchronization therapy (red) had lower risk for ventricular arrhythmia (VA)
versus those with lower changes in RWT (blue). The values in the parentheses are
Kaplan-Meier event rates.
TABLE 6 RWT Change During 12 Months and Risk of
Subsequent VAs
Outcome
(Number of Events) HR* 95% CI p Value
VT/VF (n ¼ 153) 0.66 0.45–0.95 0.027
VT $200/VF (n ¼ 95) 0.68 0.41–1.14 0.141
VT/VF/death (n ¼ 194) 0.64 0.46–0.89 0.009
VT (n ¼ 133) 0.68 0.46–1.00 0.052
VF (n ¼ 39) 0.51 0.23–1.16 0.108
*HR per 10% increase in RWT at 12 months compared with baseline. Adjusted for
CRT-D therapy, female sex, glomerular ﬁltration rate, previous myocardial
infarction, New York Heart Association functional class, QRS duration $150 ms,
SBP, previous VA, and age at enrollment.
Abbreviations as in Tables 1 and 2.
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309response was signiﬁcantly lower in those with
increased RWT (greater than the upper tertile percent
change in RWT) compared with those with lower
changes in RWT at 12 months. Accordingly, in a
multivariable model (Table 6), every 10% increase of
RWT at 12monthswith CRT-Dwas associatedwith 34%
(p ¼ 0.027) and 36% (p ¼ 0.009) reductions in the rates
of subsequent VA events and subsequent VA/death,
respectively.
Baseline RWT was a signiﬁcant predictor of VT/VF
in both the ischemic and nonischemic subgroups. The
HR for the ischemic subgroup was 1.11 (95% CI: 1.04 to
1.19; p ¼ 0.001) and for the nonischemic subgroup was
1.12 (95% CI: 1.06 to 1.18; p < 0.0001; p for
interaction ¼ 0.937). The same ﬁnding was evident
when the change of RWT at 12 months was assessed;
hence, RWT increase at 12 months was associated
with risk reduction for VT/VF in both subgroups (p for
interaction ¼ 0.478).
DISCUSSION
The present study provided several important novel
ﬁndings regarding the prognostic importance of LV
geometry and its relation to VA in patients with mild
HF (LVEF #30%) and LBBB conﬁguration: 1) RWT was
the best echocardiographic predictor for VA events
compared with commonly used echocardiographic
measurements; 2) RWT was inversely related to the
risk of VA in patients with eccentric hypertrophy;
and 3) increased RWT after 1 year of CRT-D treatment
was related to lower risk for VA in patients with
eccentric hypertrophy (Central Illustration). These
ﬁndings were consistent among all pre-speciﬁed pa-
tient subgroups and when an alternative RWT for-
mula was used (including the dimensions of the
posterior wall and the interventricular septum).
The relation between LV geometry and clinical
outcome was originally assessed in healthy controls
participating in the Framingham Heart Study. The
development of concentric hypertrophy was shown
to carry the worst prognosis, followed by eccentric
hypertrophy, concentric remodeling, and normal
morphology; these groupings were deﬁned by distinct
cutoffs related to relative LV mass and relative wall
thickness (13). Several studies (8,14,15) described the
same relation between the remodeling morphologies
and cardiac morbidity and mortality, primarily in
patients with hypertension.
There is a paucity of data, however, on the relation
between LV geometry, in particular eccentric hyper-
trophy, and VA. St. John Sutton et al. (16) showed
that in patients with ischemic cardiomyopathy,
larger end-diastolic and end-systolic volumes wereassociated with increased incidence of VT and pre-
mature ventricular complexes; however, in a multi-
variable model, LVEF was a stronger predictor for this
outcome. Draper et al. (17) demonstrated that in
patients with a reduced LVEF (#45%) and ICD ther-
apy, eccentric hypertrophy was associated with a
higher risk for VT/VF compared with normal and
concentric remodeling. Yet, those investigators did
not report the effect of different RWT values within
the eccentric hypertrophy group nor was there a CRT-
D therapy group.
In the present study, almost all of the patients had
eccentric hypertrophy (RWT <0.32), and only a few
had normal geometry (0.32 < RWT <0.42), as one
would expect in the case of severe systolic HF leading
CENTRAL ILLUSTRATION Relative Wall Thickness and Risk of Ventricular Arrhythmias
CRT Effect
Increased Risk of Ventricular Arrhythmia
RV            LV
Decreasing RWT
Reentry             Fibrosis             LVEDD            Wall Thickness
    Eccentric Hypertrophy                                                                                                Normal
Biton, Y. et al. J Am Coll Cardiol. 2016; 67(3):303–12.
Remodeling of the left ventricle (LV) can be determined by echocardiographic measurement of relative wall thickness (RWT); as RWT decreases (leading to eccentric
hypertrophy) and left ventricular end-diastolic diameter (LVEDD) increases, the risk of ventricular arrhythmias rises. In patients with heart failure, the remodeling
process induces ﬁbrosis and scar formation that serves as a substrate for reentry circuits. Treatment with cardiac resynchronization therapy (CRT) helps reverse these
effects. RV ¼ right ventricle.
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310to dilated cardiomyopathy (18). Therefore, we were
able to further support previous observations and
provide incremental data demonstrating that in
patients with mild HF, with either ischemic or non-
ischemic cardiomyopathy, the magnitude of RWT
(a measure of baseline eccentric hypertrophy) rather
than just the categorization of LV geometry itself,
could predict the risk for VA and mortality. We
showed an inverse relationship between RWT and VA
risk: the lower the RWT measured, the higher the risk
for VA. This conclusion is also supported by our
observation that among patients treated with CRT-D,
a pronounced increase in RWT after 1 year (i.e., the
heart becomes less “eccentric” and more normal in
conﬁguration) was associated with a signiﬁcant
reduction in the risk for VA or death.
Several mechanisms could potentially explain our
ﬁndings. The remodeling process of the diseased
heart is characterized by the replacement ofnecrotized myocytes with ﬁbroblasts, which in turn
increase collagen formation throughout the heart
(19,20). This process induces ﬁbrosis and scar forma-
tion that can potentially cause even healthy myocytes
to undergo apoptosis; this paradigm is known to serve
as a substrate for reentry circuits, early after-
depolarizations, and the formation of VA, especially
in patients with enlarged ventricles with slowed im-
pulse propagation velocities over ﬁbrotic tissue
(21,22). Additional evidence shows that ﬁbrosis
enhances the ability of oxidative stress to induce
spontaneous VF (23). Previous clinical trials showed a
correlation between the degree of ﬁbrosis, as
measured by cardiac magnetic resonance imaging,
and the risk of VA (24,25). The risk for VA also was
associated with the degree of adverse remodeling, as
measured by LVEDV in other trials (26). RWT is
directly correlated with wall thickness and inversely
correlated with LVEDV. Thus, among patients with
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: RWT is inversely
related to the risk of VT in patients with systolic HF and LBBB.
TRANSLATIONAL OUTLOOK: Prospective clinical studies are
necessary to conﬁrm the therapeutic implications of RWT in pa-
tients with eccentric hypertrophy with regard to pharmacological
treatment, ICD programming, and cardiac resynchronization.
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311eccentric hypertrophy, the magnitude of RWT can
mirror the extent of LV ﬁbrosis and scarring on one
hand and the extent of the remodeling process on the
other hand. In the current study, both of these mea-
sures (wall thickness as a measure of wall ﬁbrosis
and diastolic diameter as a measure of remodeling)
were independently associated with the risk of VA.
Importantly, RWT had a higher predictive capacity
compared with its own components. Thus, patients
with very lowRWThave larger LV volumes and thinner
ﬁbrotic walls, pre-disposing the patients to VA.
STUDY LIMITATIONS. First, this was a retrospective,
nonrandomized post-hoc study. Although multivar-
iate analysis showed higher risk of VA for patients
with low RWT, after adjustment for many con-
founders, this was not a prospective trial and so
possible unmeasured confounders may have biased
the results; therefore, our results should be inter-
preted as hypothesis generating. Second, we only
included patients with LBBB morphology because
CRT-D beneﬁt was shown to be limited to this sub-
group; thus, we excluded approximately one-third of
the original study patients. It should be noted that
LBBB was not a pre-speciﬁed variable in the
MADIT-CRT study. Lastly, the goal of our research
was to show the incremental value of RWT compared
with other echocardiographic variables and not
necessarily to comprehensively develop the best
model for the prediction of VT/VF.
Further studies, preferably randomized controlled
clinical trials, are needed to corroborate our ﬁndings,provide better understanding of the relationship be-
tween RWT and VA, and more clearly deﬁne the
evolution of RWT in patients with CRT therapy.
CONCLUSIONS
Deﬁning the baseline degree of eccentric hypertrophy
using RWT measurement can be useful for prediction
of VA in patients with impaired LVEF and mild HF.
Furthermore, among patients implanted with a CRT-
D device, the magnitude of RWT increase attributed
to CRT-D can predict VA risk as well.
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